Hua Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hua Zhang has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Kwok-Kin Wong
Division of Hematology & Medical Oncology, NYU Langone Perlmutter Cancer Center, New York, USA
7 shared publications Han Han
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
6 shared publicationsVamsidhar Velcheti
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
5 shared publications- Kristen Labbe
Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY, USA
4 shared publications Chenchen Guo
State Key Laboratory of Cell Biology, Chinese Academy of Sciences , Shanghai 200031 , China
3 shared publicationsFei Li
Department of Pathology, School of Basic Medical Sciences, Fudan University , Shanghai 200032 , China
3 shared publications
Latest Publications
- Open Access
- 18 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Decoding spatial transcriptomics across multicellular and subcellular resolutions
Current whole-genome spatial transcriptomics (ST) platforms, which range from multicellular (e.g., Visium) to subcellular resolution (e.g., Visium HD, Stereo-seq), face significant challenges in accurately decomposing or aggregating spots into single cells-the fundamental units of biological activity. To date, most existing computational methods operate at the spot level, and no method has effectively reconstructed transcriptomes at single-cell resolution. In this study, we present STARS (Spatial Transcriptomics across Resolutions for Single Cells). Leveraging Vision Transformer model and contrastive learning, STARS combines high-resolution histology images with spot-level transcriptomics data to reconstruct single-cell-level gene expression from multicellular and subcellular platforms. We demonstrate the advantage of our single-cell-level method using in-house datasets of mouse lung from 3 ST platforms (Visium, Visium HD and Stereo-seq) and additional public datasets. STARS is applied at tissue, individual cell, and molecular levels. At the tissue level, STARS identifies regions of interest, such as specific tissue structures or immune regions. At the individual cell level, STARS identifies immune cells-including CD4/CD8 T cells and cancer-associated fibroblasts (CAFs)-distinguishing two CAF subtypes and macrophage subtypes, including the rare SPP1+ macrophages. Additionally, STARS identifies tertiary lymphoid structures in colorectal cancer, linked to improved clinical outcomes, and detects shifts in immune cell populations between influenza infection and bacterial superinfection in mouse lung tissue. At the molecular level, we demonstrate improved separation of cell types, and differential gene expression analysis identified cell-type-specific markers with greater accuracy. These results underscore the robustness of our method, providing biologically relevant insights into tissue architecture and gene expression at the single-cell level, advancing the downstream analysis of spatial transcriptomics across resolutions.
- 18 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessDecoding spatial transcriptomics across multicellular and subcellular resolutions
Current whole-genome spatial transcriptomics (ST) platforms, which range from multicellular (e.g., Visium) to subcellular resolution (e.g., Visium HD, Stereo-seq), face significant challenges in accurately decomposing or aggregating spots into single cells-the fundamental units of biological activity. To date, most existing computational methods operate at the spot level, and no method has effectively reconstructed transcriptomes at single-cell resolution. In this study, we present STARS (Spatial Transcriptomics across Resolutions for Single Cells). Leveraging Vision Transformer model and contrastive learning, STARS combines high-resolution histology images with spot-level transcriptomics data to reconstruct single-cell-level gene expression from multicellular and subcellular platforms. We demonstrate the advantage of our single-cell-level method using in-house datasets of mouse lung from 3 ST platforms (Visium, Visium HD and Stereo-seq) and additional public datasets. STARS is applied at tissue, individual cell, and molecular levels. At the tissue level, STARS identifies regions of interest, such as specific tissue structures or immune regions. At the individual cell level, STARS identifies immune cells-including CD4/CD8 T cells and cancer-associated fibroblasts (CAFs)-distinguishing two CAF subtypes and macrophage subtypes, including the rare SPP1+ macrophages. Additionally, STARS identifies tertiary lymphoid structures in colorectal cancer, linked to improved clinical outcomes, and detects shifts in immune cell populations between influenza infection and bacterial superinfection in mouse lung tissue. At the molecular level, we demonstrate improved separation of cell types, and differential gene expression analysis identified cell-type-specific markers with greater accuracy. These results underscore the robustness of our method, providing biologically relevant insights into tissue architecture and gene expression at the single-cell level, advancing the downstream analysis of spatial transcriptomics across resolutions.
- Open Access
- 6 November 2023
- Published by Oxford University Press (OUP) in National Science Review
- Vol. 10 (12) , nwac224
Correction to: Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis
This is a correction to: Yujuan Jin, Qiqi Zhao, Weikang Zhu, Yan Feng, Tian Xiao, Peng Zhang, Liyan Jiang, Yingyong Hou, Chenchen Guo, Hsinyi Huang, Yabin Chen, Xinyuan Tong, Jiayu Cao, Fei Li, Xueliang Zhu, Jun Qin, Dong Gao, Xin-Yuan Liu, Hua Zhang, Luonan Chen, Roman K Thomas, Kwok-Kin Wong, Lei Zhang, Yong Wang, Liang Hu, Hongbin Ji, Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis, National Science Review, Volume 9, Issue 7, July 2022, nwab232, https://doi.org/10.1093/nsr/nwab232
- 6 November 2023
- Published by Oxford University Press (OUP) in National Science Review
- Vol. 10 (12) , nwac224
Open AccessCorrection to: Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis
This is a correction to: Yujuan Jin, Qiqi Zhao, Weikang Zhu, Yan Feng, Tian Xiao, Peng Zhang, Liyan Jiang, Yingyong Hou, Chenchen Guo, Hsinyi Huang, Yabin Chen, Xinyuan Tong, Jiayu Cao, Fei Li, Xueliang Zhu, Jun Qin, Dong Gao, Xin-Yuan Liu, Hua Zhang, Luonan Chen, Roman K Thomas, Kwok-Kin Wong, Lei Zhang, Yong Wang, Liang Hu, Hongbin Ji, Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis, National Science Review, Volume 9, Issue 7, July 2022, nwab232, https://doi.org/10.1093/nsr/nwab232
- Open Access
- 15 December 2022
- Published by Elsevier in Cancer Cell
- Vol. 41 (1) , 88-105.e8
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
- 15 December 2022
- Published by Elsevier in Cancer Cell
- Vol. 41 (1) , 88-105.e8
Open AccessKMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition
- Open Access
- 8 September 2022
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 10 (9) , e004913
Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
Background: Small cell lung cancer (SCLC) is a deadly disease with a 5-year survival of less than 7%. The addition of immunotherapy to chemotherapy was recently approved as first-line treatment; however, the improved clinical benefit is modest, highlighting an urgent need for new treatment strategies. Nemvaleukin alfa, a novel engineered interleukin-2 fusion protein currently in phase I–III studies, is designed to selectively expand cytotoxic natural killer (NK) cells and CD8+ T cells. Here, using a novel SCLC murine model, we investigated the effects of a mouse version of nemvaleukin (mNemvaleukin) on tumor growth and antitumor immunity. Methods: A novel Rb1 −/− p53 −/− p130 −/− SCLC model that mimics human disease was generated. After confirming tumor burden by MRI, mice were randomized into four treatment groups: vehicle, mNemvaleukin alone, chemotherapy (cisplatin+etoposide) alone, or the combination of mNemvaleukin and chemotherapy. Tumor growth was measured by MRI and survival was recorded. Tumor-infiltrating lymphocytes and peripheral blood immune cells were analyzed by flow cytometry. Cytokine and chemokine secretion were quantified and transcriptomic analysis was performed to characterize the immune gene signatures. Results: mNemvaleukin significantly inhibited SCLC tumor growth, which was further enhanced by the addition of chemotherapy. Combining mNemvaleukin with chemotherapy provided the most significant survival benefit. Profiling of tumor-infiltrating lymphocytes revealed mNemvaleukin expanded the total number of tumor-infiltrating NK and CD8+ T cells. Furthermore, mNemvaleukin increased the frequencies of activated and proliferating NK and CD8+ T cells in tumors. Similar immune alterations were observed in the peripheral blood of mNemvaleukin-treated mice. Of note, combining mNemvaleukin with chemotherapy had the strongest effects in activating effector and cytotoxic CD8+ T cells. mNemvaleukin alone, and in combination with chemotherapy, promoted proinflammatory cytokine and chemokine production, which was further confirmed by transcriptomic analysis. Conclusions: mNemvaleukin, a novel cytokine-based immunotherapy, significantly inhibited murine SCLC tumor growth and prolonged survival, which was further enhanced by the addition of chemotherapy. mNemvaleukin alone, and in combination with chemotherapy, drove a strong antitumor immune program elicited by cytotoxic immune cells. Our findings support the evaluation of nemvaleukin alone or in combination with chemotherapy in clinical trials for the treatment of SCLC.
- 8 September 2022
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 10 (9) , e004913
Open AccessNemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
Background: Small cell lung cancer (SCLC) is a deadly disease with a 5-year survival of less than 7%. The addition of immunotherapy to chemotherapy was recently approved as first-line treatment; however, the improved clinical benefit is modest, highlighting an urgent need for new treatment strategies. Nemvaleukin alfa, a novel engineered interleukin-2 fusion protein currently in phase I–III studies, is designed to selectively expand cytotoxic natural killer (NK) cells and CD8+ T cells. Here, using a novel SCLC murine model, we investigated the effects of a mouse version of nemvaleukin (mNemvaleukin) on tumor growth and antitumor immunity. Methods: A novel Rb1 −/− p53 −/− p130 −/− SCLC model that mimics human disease was generated. After confirming tumor burden by MRI, mice were randomized into four treatment groups: vehicle, mNemvaleukin alone, chemotherapy (cisplatin+etoposide) alone, or the combination of mNemvaleukin and chemotherapy. Tumor growth was measured by MRI and survival was recorded. Tumor-infiltrating lymphocytes and peripheral blood immune cells were analyzed by flow cytometry. Cytokine and chemokine secretion were quantified and transcriptomic analysis was performed to characterize the immune gene signatures. Results: mNemvaleukin significantly inhibited SCLC tumor growth, which was further enhanced by the addition of chemotherapy. Combining mNemvaleukin with chemotherapy provided the most significant survival benefit. Profiling of tumor-infiltrating lymphocytes revealed mNemvaleukin expanded the total number of tumor-infiltrating NK and CD8+ T cells. Furthermore, mNemvaleukin increased the frequencies of activated and proliferating NK and CD8+ T cells in tumors. Similar immune alterations were observed in the peripheral blood of mNemvaleukin-treated mice. Of note, combining mNemvaleukin with chemotherapy had the strongest effects in activating effector and cytotoxic CD8+ T cells. mNemvaleukin alone, and in combination with chemotherapy, promoted proinflammatory cytokine and chemokine production, which was further confirmed by transcriptomic analysis. Conclusions: mNemvaleukin, a novel cytokine-based immunotherapy, significantly inhibited murine SCLC tumor growth and prolonged survival, which was further enhanced by the addition of chemotherapy. mNemvaleukin alone, and in combination with chemotherapy, drove a strong antitumor immune program elicited by cytotoxic immune cells. Our findings support the evaluation of nemvaleukin alone or in combination with chemotherapy in clinical trials for the treatment of SCLC.
- Open Access
- 4 January 2022
- Published by Oxford University Press (OUP) in National Science Review
- Vol. 9 (7) , nwab232
Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis
Small-cell lung cancer (SCLC) is a recalcitrant cancer characterized by high metastasis. However, the exact cell type contributing to metastasis remains elusive. Using a Rb1L/L/Trp53L/L mouse model, we identify the NCAMhiCD44lo/– subpopulation as the SCLC metastasizing cell (SMC), which is progressively transitioned from the non-metastasizing NCAMloCD44hi cell (non-SMC). Integrative chromatin accessibility and gene expression profiling studies reveal the important role of the SWI/SNF complex, and knockout of its central component, Brg1, significantly inhibits such phenotypic transition and metastasis. Mechanistically, TAZ is silenced by the SWI/SNF complex during SCLC malignant progression, and its knockdown promotes SMC transition and metastasis. Importantly, ectopic TAZ expression reversely drives SMC-to-non-SMC transition and alleviates metastasis. Single-cell RNA-sequencing analyses identify SMC as the dominant subpopulation in human SCLC metastasis, and immunostaining data show a positive correlation between TAZ and patient prognosis. These data uncover high SCLC plasticity and identify TAZ as the key molecular switch in orchestrating SCLC phenotypic transition and metastasis.
- 4 January 2022
- Published by Oxford University Press (OUP) in National Science Review
- Vol. 9 (7) , nwab232
Open AccessIdentification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis
Small-cell lung cancer (SCLC) is a recalcitrant cancer characterized by high metastasis. However, the exact cell type contributing to metastasis remains elusive. Using a Rb1L/L/Trp53L/L mouse model, we identify the NCAMhiCD44lo/– subpopulation as the SCLC metastasizing cell (SMC), which is progressively transitioned from the non-metastasizing NCAMloCD44hi cell (non-SMC). Integrative chromatin accessibility and gene expression profiling studies reveal the important role of the SWI/SNF complex, and knockout of its central component, Brg1, significantly inhibits such phenotypic transition and metastasis. Mechanistically, TAZ is silenced by the SWI/SNF complex during SCLC malignant progression, and its knockdown promotes SMC transition and metastasis. Importantly, ectopic TAZ expression reversely drives SMC-to-non-SMC transition and alleviates metastasis. Single-cell RNA-sequencing analyses identify SMC as the dominant subpopulation in human SCLC metastasis, and immunostaining data show a positive correlation between TAZ and patient prognosis. These data uncover high SCLC plasticity and identify TAZ as the key molecular switch in orchestrating SCLC phenotypic transition and metastasis.
- 28 July 2021
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (8) , 1111-1112
Response to Huang, Rivero-Hinojosa, Ma, et al
- 28 July 2021
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (8) , 1111-1112
Response to Huang, Rivero-Hinojosa, Ma, et al
- 11 March 2021
- Published by Springer Nature in Oncogene
- Vol. 40 (16) , 2817-2829
Recent advances in preclinical models for lung squamous cell carcinoma
Lung squamous cell carcinoma (LUSC) represents a major subtype of non-small cell lung cancer with limited treatment options. Previous studies have elucidated the complex genetic landscape of LUSC and revealed multiple altered genes and pathways. However, in stark contrast to lung adenocarcinoma, few targetable driver mutations have been established so far and targeted therapies for LUSC remain unsuccessful. Immunotherapy has revolutionized LUSC treatment and is currently approved as the new standard of care. To gain a better understanding of the LUSC biology, improved modeling systems are urgently needed. Preclinical models, particularly those mimicking human disease with an intact tumor immune microenvironment, are an invaluable tool to study cancer development and evaluate new therapeutic targets. Here, we discuss recent advances in LUSC preclinical models, with a focus on genetically engineered mouse models (GEMMs) and organoids, in the context of evolving precision medicine and immunotherapy.
- 11 March 2021
- Published by Springer Nature in Oncogene
- Vol. 40 (16) , 2817-2829
Recent advances in preclinical models for lung squamous cell carcinoma
Lung squamous cell carcinoma (LUSC) represents a major subtype of non-small cell lung cancer with limited treatment options. Previous studies have elucidated the complex genetic landscape of LUSC and revealed multiple altered genes and pathways. However, in stark contrast to lung adenocarcinoma, few targetable driver mutations have been established so far and targeted therapies for LUSC remain unsuccessful. Immunotherapy has revolutionized LUSC treatment and is currently approved as the new standard of care. To gain a better understanding of the LUSC biology, improved modeling systems are urgently needed. Preclinical models, particularly those mimicking human disease with an intact tumor immune microenvironment, are an invaluable tool to study cancer development and evaluate new therapeutic targets. Here, we discuss recent advances in LUSC preclinical models, with a focus on genetically engineered mouse models (GEMMs) and organoids, in the context of evolving precision medicine and immunotherapy.
- Open Access
- 3 March 2021
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (4) , 503-504
Response to Alpert and Taioli
Kristen E Labbe, MPH, Hua Zhang, MD, PhD; Response to Alpert and Taioli, JNCI: Journal of the National Cancer Institute, , djab031, https://doi.org/10.1093/jnci
- 3 March 2021
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (4) , 503-504
Open AccessResponse to Alpert and Taioli
Kristen E Labbe, MPH, Hua Zhang, MD, PhD; Response to Alpert and Taioli, JNCI: Journal of the National Cancer Institute, , djab031, https://doi.org/10.1093/jnci
- Open Access
- 6 January 2021
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (3) , 344-345
Response to Cottu, Bozec, Basse, and Paoletti
Hua Zhang, MD, PhD, Han Han, MD, Tianhui He, BS, Kristen E Labbe, MPH, Adrian V Hernandez, MD, PhD, Haiquan Chen, MD, PhD, Vamsidhar Velcheti, MD, Justin Stebbi
- 6 January 2021
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (3) , 344-345
Open AccessResponse to Cottu, Bozec, Basse, and Paoletti
Hua Zhang, MD, PhD, Han Han, MD, Tianhui He, BS, Kristen E Labbe, MPH, Adrian V Hernandez, MD, PhD, Haiquan Chen, MD, PhD, Vamsidhar Velcheti, MD, Justin Stebbi
- 2 November 2020
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (4) , 371-380
Clinical Characteristics and Outcomes of COVID-19–Infected Cancer Patients: A Systematic Review and Meta-Analysis
Background: Previous studies have indicated coronavirus disease 2019 (COVID-19) patients with cancer have a high fatality rate.Methods: We conducted a systematic review of studies that reported fatalities in COVID-19 patients with cancer. A comprehensive meta-analysis that assessed the overall case fatality rate and associated risk factors was performed. Using individual patient data, univariate and multivariable logistic regression analyses were used to estimate odds ratios (OR) for each variable with outcomes.Results: We included 15 studies with 3019 patients, of which 1628 were men; 41.0% were from the United Kingdom and Europe, followed by the United States and Canada (35.7%), and Asia (China, 23.3%). The overall case fatality rate of COVID-19 patients with cancer measured 22.4% (95% confidence interval [CI] = 17.3% to 28.0%). Univariate analysis revealed age (OR = 3.57, 95% CI = 1.80 to 7.06), male sex (OR = 2.10, 95% CI = 1.07 to 4.13), and comorbidity (OR = 2.00, 95% CI = 1.04 to 3.85) were associated with increased risk of severe events (defined as the individuals being admitted to the intensive care unit, or requiring invasive ventilation, or death). In multivariable analysis, only age greater than 65 years (OR = 3.16, 95% CI = 1.45 to 6.88) and being male (OR = 2.29, 95% CI = 1.07 to 4.87) were associated with increased risk of severe events.Conclusions: Our analysis demonstrated that COVID-19 patients with cancer have a higher fatality rate compared with that of COVID-19 patients without cancer. Age and sex appear to be risk factors associated with a poorer prognosis.
- 2 November 2020
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 113 (4) , 371-380
Clinical Characteristics and Outcomes of COVID-19–Infected Cancer Patients: A Systematic Review and Meta-Analysis
Background: Previous studies have indicated coronavirus disease 2019 (COVID-19) patients with cancer have a high fatality rate.Methods: We conducted a systematic review of studies that reported fatalities in COVID-19 patients with cancer. A comprehensive meta-analysis that assessed the overall case fatality rate and associated risk factors was performed. Using individual patient data, univariate and multivariable logistic regression analyses were used to estimate odds ratios (OR) for each variable with outcomes.Results: We included 15 studies with 3019 patients, of which 1628 were men; 41.0% were from the United Kingdom and Europe, followed by the United States and Canada (35.7%), and Asia (China, 23.3%). The overall case fatality rate of COVID-19 patients with cancer measured 22.4% (95% confidence interval [CI] = 17.3% to 28.0%). Univariate analysis revealed age (OR = 3.57, 95% CI = 1.80 to 7.06), male sex (OR = 2.10, 95% CI = 1.07 to 4.13), and comorbidity (OR = 2.00, 95% CI = 1.04 to 3.85) were associated with increased risk of severe events (defined as the individuals being admitted to the intensive care unit, or requiring invasive ventilation, or death). In multivariable analysis, only age greater than 65 years (OR = 3.16, 95% CI = 1.45 to 6.88) and being male (OR = 2.29, 95% CI = 1.07 to 4.87) were associated with increased risk of severe events.Conclusions: Our analysis demonstrated that COVID-19 patients with cancer have a higher fatality rate compared with that of COVID-19 patients without cancer. Age and sex appear to be risk factors associated with a poorer prognosis.